IBDEI0IR ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,8440,2)
;;=^5015763
;;^UTILITY(U,$J,358.3,8441,0)
;;=N32.81^^39^398^84
;;^UTILITY(U,$J,358.3,8441,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8441,1,3,0)
;;=3^Overactive Bladder
;;^UTILITY(U,$J,358.3,8441,1,4,0)
;;=4^N32.81
;;^UTILITY(U,$J,358.3,8441,2)
;;=^5015652
;;^UTILITY(U,$J,358.3,8442,0)
;;=Q61.2^^39^398^88
;;^UTILITY(U,$J,358.3,8442,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8442,1,3,0)
;;=3^Polycystic Kidney,Adult Type
;;^UTILITY(U,$J,358.3,8442,1,4,0)
;;=4^Q61.2
;;^UTILITY(U,$J,358.3,8442,2)
;;=^5018796
;;^UTILITY(U,$J,358.3,8443,0)
;;=N41.1^^39^398^92
;;^UTILITY(U,$J,358.3,8443,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8443,1,3,0)
;;=3^Prostatitis,Chronic
;;^UTILITY(U,$J,358.3,8443,1,4,0)
;;=4^N41.1
;;^UTILITY(U,$J,358.3,8443,2)
;;=^186931
;;^UTILITY(U,$J,358.3,8444,0)
;;=N11.9^^39^398^100
;;^UTILITY(U,$J,358.3,8444,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8444,1,3,0)
;;=3^Pyelonephritis,Chronic,Unspec
;;^UTILITY(U,$J,358.3,8444,1,4,0)
;;=4^N11.9
;;^UTILITY(U,$J,358.3,8444,2)
;;=^5015574
;;^UTILITY(U,$J,358.3,8445,0)
;;=N20.9^^39^398^118
;;^UTILITY(U,$J,358.3,8445,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8445,1,3,0)
;;=3^Urinary Calculus,Unspec
;;^UTILITY(U,$J,358.3,8445,1,4,0)
;;=4^N20.9
;;^UTILITY(U,$J,358.3,8445,2)
;;=^5015610
;;^UTILITY(U,$J,358.3,8446,0)
;;=R97.20^^39^398^31
;;^UTILITY(U,$J,358.3,8446,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8446,1,3,0)
;;=3^Elevated PSA
;;^UTILITY(U,$J,358.3,8446,1,4,0)
;;=4^R97.20
;;^UTILITY(U,$J,358.3,8446,2)
;;=^334262
;;^UTILITY(U,$J,358.3,8447,0)
;;=N52.36^^39^398^36
;;^UTILITY(U,$J,358.3,8447,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8447,1,3,0)
;;=3^Erectile Dysfunction After Interstitial Seed Therapy
;;^UTILITY(U,$J,358.3,8447,1,4,0)
;;=4^N52.36
;;^UTILITY(U,$J,358.3,8447,2)
;;=^5138933
;;^UTILITY(U,$J,358.3,8448,0)
;;=N52.37^^39^398^37
;;^UTILITY(U,$J,358.3,8448,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8448,1,3,0)
;;=3^Erectile Dysfunction After Prostate Ablative Therapy
;;^UTILITY(U,$J,358.3,8448,1,4,0)
;;=4^N52.37
;;^UTILITY(U,$J,358.3,8448,2)
;;=^5138934
;;^UTILITY(U,$J,358.3,8449,0)
;;=N52.35^^39^398^38
;;^UTILITY(U,$J,358.3,8449,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8449,1,3,0)
;;=3^Erectile Dysfunction After Radiation Therapy
;;^UTILITY(U,$J,358.3,8449,1,4,0)
;;=4^N52.35
;;^UTILITY(U,$J,358.3,8449,2)
;;=^5138932
;;^UTILITY(U,$J,358.3,8450,0)
;;=R31.21^^39^398^58
;;^UTILITY(U,$J,358.3,8450,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8450,1,3,0)
;;=3^Hematuria,Microscopic,Asymptomatic
;;^UTILITY(U,$J,358.3,8450,1,4,0)
;;=4^R31.21
;;^UTILITY(U,$J,358.3,8450,2)
;;=^5139198
;;^UTILITY(U,$J,358.3,8451,0)
;;=R31.29^^39^398^59
;;^UTILITY(U,$J,358.3,8451,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8451,1,3,0)
;;=3^Hematuria,Microscopic,Other
;;^UTILITY(U,$J,358.3,8451,1,4,0)
;;=4^R31.29
;;^UTILITY(U,$J,358.3,8451,2)
;;=^5019327
;;^UTILITY(U,$J,358.3,8452,0)
;;=R39.198^^39^398^72
;;^UTILITY(U,$J,358.3,8452,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8452,1,3,0)
;;=3^Micturition,Oth Difficulties
;;^UTILITY(U,$J,358.3,8452,1,4,0)
;;=4^R39.198
;;^UTILITY(U,$J,358.3,8452,2)
;;=^5019347
;;^UTILITY(U,$J,358.3,8453,0)
;;=R39.191^^39^398^74
;;^UTILITY(U,$J,358.3,8453,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0IR 3747 printed Nov 22, 2024@16:59:41 Page 2
IBDEI0IR ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,8440,2)
+2 ;;=^5015763
+3 ;;^UTILITY(U,$J,358.3,8441,0)
+4 ;;=N32.81^^39^398^84
+5 ;;^UTILITY(U,$J,358.3,8441,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,8441,1,3,0)
+8 ;;=3^Overactive Bladder
+9 ;;^UTILITY(U,$J,358.3,8441,1,4,0)
+10 ;;=4^N32.81
+11 ;;^UTILITY(U,$J,358.3,8441,2)
+12 ;;=^5015652
+13 ;;^UTILITY(U,$J,358.3,8442,0)
+14 ;;=Q61.2^^39^398^88
+15 ;;^UTILITY(U,$J,358.3,8442,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,8442,1,3,0)
+18 ;;=3^Polycystic Kidney,Adult Type
+19 ;;^UTILITY(U,$J,358.3,8442,1,4,0)
+20 ;;=4^Q61.2
+21 ;;^UTILITY(U,$J,358.3,8442,2)
+22 ;;=^5018796
+23 ;;^UTILITY(U,$J,358.3,8443,0)
+24 ;;=N41.1^^39^398^92
+25 ;;^UTILITY(U,$J,358.3,8443,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,8443,1,3,0)
+28 ;;=3^Prostatitis,Chronic
+29 ;;^UTILITY(U,$J,358.3,8443,1,4,0)
+30 ;;=4^N41.1
+31 ;;^UTILITY(U,$J,358.3,8443,2)
+32 ;;=^186931
+33 ;;^UTILITY(U,$J,358.3,8444,0)
+34 ;;=N11.9^^39^398^100
+35 ;;^UTILITY(U,$J,358.3,8444,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,8444,1,3,0)
+38 ;;=3^Pyelonephritis,Chronic,Unspec
+39 ;;^UTILITY(U,$J,358.3,8444,1,4,0)
+40 ;;=4^N11.9
+41 ;;^UTILITY(U,$J,358.3,8444,2)
+42 ;;=^5015574
+43 ;;^UTILITY(U,$J,358.3,8445,0)
+44 ;;=N20.9^^39^398^118
+45 ;;^UTILITY(U,$J,358.3,8445,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,8445,1,3,0)
+48 ;;=3^Urinary Calculus,Unspec
+49 ;;^UTILITY(U,$J,358.3,8445,1,4,0)
+50 ;;=4^N20.9
+51 ;;^UTILITY(U,$J,358.3,8445,2)
+52 ;;=^5015610
+53 ;;^UTILITY(U,$J,358.3,8446,0)
+54 ;;=R97.20^^39^398^31
+55 ;;^UTILITY(U,$J,358.3,8446,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,8446,1,3,0)
+58 ;;=3^Elevated PSA
+59 ;;^UTILITY(U,$J,358.3,8446,1,4,0)
+60 ;;=4^R97.20
+61 ;;^UTILITY(U,$J,358.3,8446,2)
+62 ;;=^334262
+63 ;;^UTILITY(U,$J,358.3,8447,0)
+64 ;;=N52.36^^39^398^36
+65 ;;^UTILITY(U,$J,358.3,8447,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,8447,1,3,0)
+68 ;;=3^Erectile Dysfunction After Interstitial Seed Therapy
+69 ;;^UTILITY(U,$J,358.3,8447,1,4,0)
+70 ;;=4^N52.36
+71 ;;^UTILITY(U,$J,358.3,8447,2)
+72 ;;=^5138933
+73 ;;^UTILITY(U,$J,358.3,8448,0)
+74 ;;=N52.37^^39^398^37
+75 ;;^UTILITY(U,$J,358.3,8448,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,8448,1,3,0)
+78 ;;=3^Erectile Dysfunction After Prostate Ablative Therapy
+79 ;;^UTILITY(U,$J,358.3,8448,1,4,0)
+80 ;;=4^N52.37
+81 ;;^UTILITY(U,$J,358.3,8448,2)
+82 ;;=^5138934
+83 ;;^UTILITY(U,$J,358.3,8449,0)
+84 ;;=N52.35^^39^398^38
+85 ;;^UTILITY(U,$J,358.3,8449,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,8449,1,3,0)
+88 ;;=3^Erectile Dysfunction After Radiation Therapy
+89 ;;^UTILITY(U,$J,358.3,8449,1,4,0)
+90 ;;=4^N52.35
+91 ;;^UTILITY(U,$J,358.3,8449,2)
+92 ;;=^5138932
+93 ;;^UTILITY(U,$J,358.3,8450,0)
+94 ;;=R31.21^^39^398^58
+95 ;;^UTILITY(U,$J,358.3,8450,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,8450,1,3,0)
+98 ;;=3^Hematuria,Microscopic,Asymptomatic
+99 ;;^UTILITY(U,$J,358.3,8450,1,4,0)
+100 ;;=4^R31.21
+101 ;;^UTILITY(U,$J,358.3,8450,2)
+102 ;;=^5139198
+103 ;;^UTILITY(U,$J,358.3,8451,0)
+104 ;;=R31.29^^39^398^59
+105 ;;^UTILITY(U,$J,358.3,8451,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,8451,1,3,0)
+108 ;;=3^Hematuria,Microscopic,Other
+109 ;;^UTILITY(U,$J,358.3,8451,1,4,0)
+110 ;;=4^R31.29
+111 ;;^UTILITY(U,$J,358.3,8451,2)
+112 ;;=^5019327
+113 ;;^UTILITY(U,$J,358.3,8452,0)
+114 ;;=R39.198^^39^398^72
+115 ;;^UTILITY(U,$J,358.3,8452,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,8452,1,3,0)
+118 ;;=3^Micturition,Oth Difficulties
+119 ;;^UTILITY(U,$J,358.3,8452,1,4,0)
+120 ;;=4^R39.198
+121 ;;^UTILITY(U,$J,358.3,8452,2)
+122 ;;=^5019347
+123 ;;^UTILITY(U,$J,358.3,8453,0)
+124 ;;=R39.191^^39^398^74
+125 ;;^UTILITY(U,$J,358.3,8453,1,0)
+126 ;;=^358.31IA^4^2
